Evommune, Inc. (EVMN)
NYSE · Healthcare
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $171.95M
- P/E ratio
- —
- EPS
- —
- Volume
- 709,326
- 52-week high
- —
- 52-week low
- —
- Open
- $11.93
- Day high
- $12.36
- Day low
- $11.15
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | $13M | -$68.87M | -$11.22 |
| 2024 | $7M | -$66.81M | -$45.29 |
About Evommune, Inc.
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
- CEO
- Luis C. Pena
- Employees
- 48
- Country
- US
- IPO date
- Nov 6, 2025
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Evommune, Inc.'s stock price today?
- EVMN is trading at $11.53 as of Jul 20, 2026.
- What is Evommune, Inc.'s market cap?
- Evommune, Inc. (EVMN) has a market capitalization of $171.95M.
- Does Evommune, Inc. pay a dividend?
- Evommune, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Evommune, Inc. in?
- Evommune, Inc. operates in the Healthcare sector.